The Effect of Omeprazole on the Pharmacokinetics of Piroxicam Profiles with High Performance Liquid Chromatography (HPLC) Method

Authors

  • Firdaus Fahdi Institut Kesehatan Deli Husada Deli Tua
  • Herviani Sari Institut Kesehatan Deli Husada Deli Tua
  • Sulasmi Department of Pharmaceutical, Faculty of Pharmacy, Institut Kesehatan Deli Husada Deli Tua, Indonesia
  • Wahyudi Department of Pharmaceutical, Faculty of Pharmacy, Institut Kesehatan Deli Husada Deli Tua, Indonesia

DOI:

https://doi.org/10.32734/idjpcr.v3i1.4049

Keywords:

Pharmacokinetics, Inhibition of Metabolic Enzymes, Piroxicam, Omeprazole

Abstract

Piroxicam is an anti-inflammatory drug of the NSAID class that is commonly used as an analgesic and anthireumatic drug. Its use is often combined with gastric drugs, one of which is omeprazole, considering the side effects of piroxicam which can irritate the stomach. Piroxicam and omeprazole work on the same enzyme, CYP-450 so that it can affect the pharmacokinetic profile especially in the metabolic and excretion phases of piroxicam. This research is an experimental study using 3 male rabbits. Measurement of plasma levels of piroxicam drug is carried out using a High Performance’s Liquid Chromatography (HPLC) tool. The validation method is used to determine LOD and LOQ values, accuracy, and precision tests. The results of data analysis using t-tables. The results showed the value of pharmacokinetic parameters in the absorption phase increased or there were differences but did not show any significant effect on each group. While the pharmacokinetic parameter values ​​in the metabolic and excretion phases decreased and showed no differences between groups. The administration of omeprazole and piroxicam together and the administration of piroxicam which was given an hour earlier by omeprazole can inhibit the enzyme that stimulates the metabolism of piroxicam so that it affects the pharmacokinetic parameters in the absorption phase and also excretion but is not significant.

Downloads

Download data is not yet available.

References

Sumarno, “Interaksi Simetidin Terhadap Kinetika Eliminasi Parasetamol pada Kelinci, Jurnal Farmasi Indonesia, vol.3, no.1, pp.9-12. 2006.

B. D. Snyder, T. M. Polasek, and M. P. Doogue, “Drug Interactions Princeples and Practice,” Australian Prescriber, vol. 35, no. 3, pp. 85–88, June. 2012.

F. Rahmawati, R. Handayani, and V. Gosal, “Kajian Retrospektif Interaksi Obat di Rumah Sakit Pendidikan Dr. Sardjito Yogyakarta,” Majalah Farmasi Indonesia, vol. 17, no.4, pp. 177-183. 2006.

M. Pirmohamed, S. James, S. Meakin, C. Green, A.K. Scott, T.J. Walley, et al,” Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients,” BMJ, vol. 329, pp 15-19. 2004.

Aslam, M., Kaw Tan, C., and Prayitno, A.,” Farmasi Klinis (Clinical Pharmacy) Menuju Pengobatan Rasional dan Penghargaan Pilihan Pasien,” Jakarta: PT. Elex Media Komputindo. 2003.

Forceia, MA.,et al.,”Geriatric Secrets, Third Edition,” United States: Independence Square West. 2004.

Hakim, L.,” Farmakokinetik Klinik,”Yogyakarta: Bursa Ilmu. 2012.

Siswandono dan Soekardjo, B.,” Kimia Medisinal Edisi 2,” Surabaya: Airlangga University Press. 2000.

Iersa, R., “Pengaruh Vitamin C pada Profil Farmakokinetika Natrium Diklofenak Terhadap Hewan Uji Kelinci,” M.S. Thesis Universitas Sumatera Utara. Medan. 2012.

Mirakel Agatha Devi, “Pengaruh Pemberian Air Berkarbonasi Terhadap Profil Farmakokinetika Parasetamol Pada Tikus Putih Jantan,” M.S. Thesis Universitas Sanata Dharma. Yogyakarta. 2007.

Published

2020-08-17

How to Cite

Fahdi, F., Herviani Sari, Sulasmi, & Wahyudi. (2020). The Effect of Omeprazole on the Pharmacokinetics of Piroxicam Profiles with High Performance Liquid Chromatography (HPLC) Method. Indonesian Journal of Pharmaceutical and Clinical Research, 3(1), 36-41. https://doi.org/10.32734/idjpcr.v3i1.4049

Issue

Vol. 3 No. 1 (2020): Indonesian Journal of Pharmaceutical and Clinical Research

Section

Articles

Copyright (c) 2020 Indonesian Journal of Pharmaceutical and Clinical Research

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

The Authors submitting a manuscript do so on the understanding that if accepted for publication, copyright of the article shall be assigned to Indonesian Journal of Pharmaceutical and Clinical Research (IDJPCR) and Faculty of Pharmacy as well as TALENTA Publisher Universitas Sumatera Utara as publisher of the journal.

Copyright encompasses exclusive rights to reproduce and deliver the article in all form and media. The reproduction of any part of this journal, its storage in databases and its transmission by any form or media, will be allowed only with a written permission from Indonesian Journal of Pharmaceutical and Clinical Research (IDJPCR).

The Copyright Transfer Form can be downloaded here. 
The copyright form should be signed originally and sent to the Editorial Office in the form of original mail or scanned document.